BioLine Rx Ltd (XTAE:BLRX)
â‚Ş 0.123 0 (0%) Market Cap: 147.50 Mil Enterprise Value: 114.57 Mil PE Ratio: 0 PB Ratio: 2.80 GF Score: 16/100

Q4 2022 BioLine RX Ltd Earnings Call Transcript

Mar 22, 2023 / 02:00PM GMT
Release Date Price: â‚Ş0.175 (+7.36%)
Operator

Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx 2022 financial results conference call. (Operator Instructions) I would now like to turn over the call to John Lacey, Head of Investor Relations and Corporate Communications, BioLineRx. Please go ahead.

John Lacey
BioLineRx Ltd. - Head of IR & Corporate Communication

Thank you, operator. Before turning the call over to management, I would like to make the following remarks concerning forward-looking statements. All statements in this conference call, other than historical facts, are indeed forward-looking statements. The words anticipate, believe, estimate, expect, intend, guidance, competence, target, project, and other similar expressions are used typically to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and may involve and are subject to certain risks and uncertainties and other factors that may affect BioLineRx's business, financial condition, and other operating results. These include, but are not limited to,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot